Desteklenen Projeler
-
2023 - 2026 A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative 23 Therapy
-
2022 - 2025 Erken Evre Meme Kanserinde Prognozu Belirlemede CanAssist Breast Testi ile Oncotype Dx/ MammaPrint Konkordansının Belirlenmesi
-
2022 - 2025 A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD- 1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast02)
-
2021 - 2025 A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) (
-
2020 - 2025 A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)
-
2019 - 2024 EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (ClinicalTrials.gov identifier
-
2017 - 2024 Analysis of P53 gene mutations in patients with oral squamous cell carcinoma. Scientific research project supported by Higher Education Institutions,
-
2021 - 2023 A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo in Patients With HER2-Positive and PD-L1-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab- (+/- Pertuzumab) and Taxane-Based Therapy (KATE3) (ClinicalTrials.gov identifier: NCT04740918)
-
2012 - 2021 A Phase Ib/II Study of Eribulin in Combination with Cyclophosphamide in Patients with Solid Tumor Malignancies.
-
2011 - 2020 Reversing Hormone Resistance in Advanced Breast Cancer with Pazopanib. Phase II trial.
-
2013 - 2018 Regorafenib in subjects with metastatic colorectal cancer (mCRC) who have progressed after Standard therapy in Turkey, Phase III,
-
2012 - 2016 Epidemiological study including evaluation of HER2 status in gastric and gastroesophageal junction cancer tumor. Epidemiologic study